Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   GOVARESH JOURNAL   FALL 2015 , Volume 20 , Number SUPPLEMENT; Page(s) 28 To 29.
 
Paper: 

A COMPARISON BETWEEN HYBRID AND CONCOMITANT REGIMENS FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CLINICAL TRIAL

 
 
Author(s):  FAKHERI HAFEZ, MALEKI IRADJ, ALHOOEI SAMAN*, VALIZADEH SEYED MOHAMMAD, TAGHVAEI TARANG, HOSSEINI VAHID, BARI ZOHREH
 
* GUT AND LIVER RESEARCH CENTER, MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES
 
Abstract: 

Introduction: Helicobacter pylori is one of the most common bacterial infections in the world. We designed a study to compare the efficacy of 14-day hybrid regimen with 10-day concomitant therapy for H. pylori eradication in Iran.
Methods: Two hundred and fifty two patients with naive H. pylori infection were randomly divided to receive either hybrid regimen (Pantoprazole 40 mg BID and Amoxicillin 1 gr BID for 14 days, accompanied by Clarithromycin 500 mg BID and Metronidazole 500 mg BID just during the last 7 days) or concomitant regimen (Pantoprazole 40 mg, Amoxicillin 1 gr, Clarithromycin 500 mg and Metronidazole 500 mg, all twice daily for 10 days).
Eight weeks after therapy, 14C- Urease Breath test was performed to confirm eradication.
Results: According to intention to treat analysis, the eradication rates were 87.3% (95% confidence interval=81.4 – 93.1) and 80.9% (95% CI=74 - 87.8) in hybrid and concomitant groups, respectively (p= 0.38). Per-protocol eradication rates were 89.3% (95% CI=83.8 - 94.7) and 83.1% (95% CI=76.3 -89.8), respectively (p=0.19). The rates of severe side effects were not statistically different between the two groups (4% vs.8.7%).
Conclusion: Fourteen-day hybrid therapy can be considered as a nearly acceptable regimen with few severe side effects in Iran. However, it seems that the efficacy of this therapy is decreasing as the resistance rates to antibiotics are increasing. We suggest further studies to assess the efficacy of a more prolonged concomitant therapy for H. pylori eradication in Iran.

 
Keyword(s): 
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

FAKHERI, H., & MALEKI, I., & ALHOOEI, S., & VALIZADEH, S., & TAGHVAEI, T., & HOSSEINI, V., & BARI, Z. (2015). A COMPARISON BETWEEN HYBRID AND CONCOMITANT REGIMENS FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CLINICAL TRIAL. GOVARESH JOURNAL, 20(SUPPLEMENT), 28-29. https://www.sid.ir/en/journal/ViewPaper.aspx?id=509769



Vancouver: Copy

FAKHERI HAFEZ, MALEKI IRADJ, ALHOOEI SAMAN, VALIZADEH SEYED MOHAMMAD, TAGHVAEI TARANG, HOSSEINI VAHID, BARI ZOHREH. A COMPARISON BETWEEN HYBRID AND CONCOMITANT REGIMENS FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CLINICAL TRIAL. GOVARESH JOURNAL. 2015 [cited 2021July25];20(SUPPLEMENT):28-29. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=509769



IEEE: Copy

FAKHERI, H., MALEKI, I., ALHOOEI, S., VALIZADEH, S., TAGHVAEI, T., HOSSEINI, V., BARI, Z., 2015. A COMPARISON BETWEEN HYBRID AND CONCOMITANT REGIMENS FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CLINICAL TRIAL. GOVARESH JOURNAL, [online] 20(SUPPLEMENT), pp.28-29. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=509769.



 
 
Yearly Visit 38
 
 
Latest on Blog
Enter SID Blog